Cantor Fitzgerald Cuts Earnings Estimates for Disc Medicine

Disc Medicine, Inc. (NASDAQ:IRON) – Analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Disc Medicine in a note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($4.69) per share for the year, down from their previous estimate of ($4.59). Cantor Fitzgerald has a “Overweight” rating and a $132.00 price target on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

Other equities research analysts also recently issued reports about the stock. Stifel Nicolaus boosted their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Morgan Stanley reissued an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. BMO Capital Markets raised their price target on Disc Medicine from $112.00 to $120.00 and gave the stock an “outperform” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a report on Tuesday, January 21st. Finally, Scotiabank lifted their target price on Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, March 3rd. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $98.80.

Disc Medicine Stock Performance

IRON opened at $46.35 on Monday. The stock has a market capitalization of $1.60 billion, a PE ratio of -11.65 and a beta of 0.77. Disc Medicine has a one year low of $30.65 and a one year high of $68.73. The business’s 50 day moving average price is $46.54 and its 200 day moving average price is $54.93.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.03).

Hedge Funds Weigh In On Disc Medicine

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Amalgamated Bank lifted its position in shares of Disc Medicine by 38.6% during the 1st quarter. Amalgamated Bank now owns 787 shares of the company’s stock worth $39,000 after buying an additional 219 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after acquiring an additional 266 shares in the last quarter. Teacher Retirement System of Texas lifted its position in Disc Medicine by 8.9% in the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company’s stock valued at $308,000 after acquiring an additional 396 shares during the last quarter. Sterling Capital Management LLC boosted its stake in Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after acquiring an additional 503 shares in the last quarter. Finally, Arizona State Retirement System boosted its stake in Disc Medicine by 12.5% in the first quarter. Arizona State Retirement System now owns 5,315 shares of the company’s stock valued at $264,000 after acquiring an additional 590 shares in the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider William Jacob Savage sold 2,100 shares of the stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $50.17, for a total value of $105,357.00. Following the transaction, the insider now owns 66,398 shares of the company’s stock, valued at $3,331,187.66. This represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $87,873.80. Following the sale, the chief operating officer now owns 40,555 shares of the company’s stock, valued at approximately $2,213,491.90. The trade was a 3.82% decrease in their position. The disclosure for this sale can be found here. Insiders sold 356,290 shares of company stock valued at $19,336,901 in the last three months. 4.24% of the stock is owned by corporate insiders.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.